The DEA announced plans to reschedule marijuana from a Schedule I drug to a Schedule III drug. Rescheduling marijuana would not make it legal for recreational use, as Schedule III drugs are still controlled substances and subject to rules and...
Eugia US LLC – also known as AuroMedics Pharma LLC – initiated a voluntary recall of lot number 3MC23011 of Methocarbamol Injection, USP 1000 mg/10 mL (100mg/mL) (Single Dose Vial) - 10mL Vial to the consumer level due to a...
The FDA has received adverse event reports after patients used compounded semaglutide, including reports that in some cases, compounders may be using salt forms of semaglutide, including semaglutide sodium and semaglutide acetate. These salt forms are different active ingredients than...
The FDA approved the first test that uses DNA in assessing whether certain individuals may have an elevated risk of developing opioid use disorder (OUD). As part of a clinical evaluation, the AutoGenomics, Inc. AvertD test is intended to be...
The FDA warned consumers about counterfeit Ozempic found in the U.S. drug supply chain. Thousands of units have been seized so far, with the FDA advising wholesalers, retail pharmacies, health care practitioners and patients to check the products they have...
Leiters Health is voluntarily recalling 33 lots of IV vancomycin, phenylephrine, and fentanyl products at the user level due to superpotency because the bags may contain twice the labeled amount of drug. There is a reasonable probability that the use...
The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs). These medicines are used to treat people with type 2 diabetes or to help...
The FDA issued a warning that the antiseizure medications levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan) can cause a rare but serious reaction that can be life-threatening if not diagnosed and treated quickly. This reaction is...
The FDA issued a warning regarding the use of compounded ketamine products for the treatment of psychiatric disorders. Ketamine is not FDA-approved for the treatment of any psychiatric disorder. It is important to note that ketamine is a mixture of...
A key Pfizer pharmaceutical plant in North Carolina was damaged by a tornado, impacting the production of various pharmaceuticals, which will likely lead to shortages of certain medications. The plant produces anesthesia and other drugs, as well as nearly 25%...
The FDA will be requiring several updates to the prescribing information for all opioid pain medications. All opioid pain medications will note that the risk of overdose increases as the dose increases, as well as a new warning about opioid-induced...
Teva Pharmaceuticals has voluntarily recalled specific lots of various strengths of fentanyl buccal tablets CII at the consumer level due to a labeling error. This recall has been initiated because safety updates were omitted in the Product Insert/Medication Guide (MG)...
Family Dollar initiated a recall of various Advil (ibuprofen) over-the-counter products that were stored and shipped to certain stores on or around June 1, 2022 through March 31, 2023 by Family Dollar outside of labeled temperature requirements. Exposure to high...
The FDA approved Narcan (naloxone hydrochloride) 4mg nasal spray for over-the-counter (OTC) use – the first naloxone product approved for use without a prescription. Naloxone rapidly reverses the effects of opioids and is the standard treatment for opioid overdose. As...
The FDA will soon require opioid manufacturers to make prepaid mail-back envelopes available to outpatient pharmacies and other dispensers as an additional opioid analgesic disposal option for patients. The FDA issued notice to all opioid manufacturers that they are required...
